MedTrace Logo

Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A Patients

NCT06574984 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 900

Last updated 2026-02-13

No results posted yet for this study

Summary

The study has descriptive purposes, with aim of assessing how turoctocog alfa is used in the everyday practice and to provide a baseline for the management of haemophilia A and does not involve any change in the clinical management of participants. Data will be extrapolated from the existing paper based medical records and uploaded to an electronic database specifically created for the study. Baseline information/history will be recorded at time of switching from previous FVIII replacement therapy to turoctocog alfa from the enrolled participants and outcomes will be collected according to participants visit format.

Conditions

  • Congenital Bleeding Disorder
  • Haemophilia A

Interventions

DRUG

Turoctocog alfa

Turoctocog alfa was administered intravenously.

Sponsors & Collaborators

Principal Investigators

  • Clinical Transparency (dept. 2834) · Novo Nordisk A/S

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-10
Primary Completion
2026-02-27
Completion
2026-04-30

Countries

  • Iraq

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06574984 on ClinicalTrials.gov